In the latest trading session,, 0.93 million IGC Pharma Inc (AMEX:IGC) shares changed hands as the company’s beta touched 1.28. With the company’s most recent per share price at $0.38 changed hands at -$0.05 or -9.73% at last look, the market valuation stands at $29.12M. IGC’s current price is a discount, trading about -139.47% off its 52-week high of $0.91. The share price had its 52-week low at $0.25, which suggests the last value was 34.21% up since then. When we look at IGC Pharma Inc’s average trading volume, we note the 10-day average is 0.19 million shares, with the 3-month average coming to 207.35K.
Analysts gave the IGC Pharma Inc (IGC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IGC as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. IGC Pharma Inc’s EPS for the current quarter is expected to be -0.03.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IGC Pharma Inc (AMEX:IGC) trade information
Instantly IGC was in red as seen in intraday trades today. With action -5.87%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 37.45%, with the 5-day performance at -5.87% in the red. However, in the 30-day time frame, IGC Pharma Inc (AMEX:IGC) is -17.91% down. Looking at the short shares, we see there were 1.17 million shares sold at short interest cover period of 6.9 days.
IGC Pharma Inc (IGC) estimates and forecasts
Year-over-year growth is forecast to reach -0.40% down from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 310k. 2 analysts are of the opinion that IGC Pharma Inc’s revenue for the current quarter will be 260k.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -13.79%. The 2024 estimates are for IGC Pharma Inc earnings to increase by 45.45%.
IGC Dividends
IGC Pharma Inc is expected to release its next quarterly earnings report on 2024-Nov-07.
IGC Pharma Inc (AMEX:IGC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 7.92% of IGC Pharma Inc shares while 21.66% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 23.52%. There are 21.66% institutions holding the IGC Pharma Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-03-31, the company held 1.1227% of the shares, roughly 0.72 million IGC shares worth $0.29 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 1.0124% or 0.65 million shares worth $0.26 million as of 2024-03-31.
Among Mutual Funds, the top two as of Mar 31, 2024 were Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund . With 630.22 shares estimated at $0.24 million under it, the former controlled 1.59% of total outstanding shares. On the other hand, Fidelity Extended Market Index Fund held about 0.72% of the shares, roughly 286.87 shares worth around $0.11 million.
